to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
See who made this week's list
The United States is joining the rest of the world in its approach to patent filings. But what does that mean in the completely global world of medical and pharmaceutical treatments, therapies and technologies depending on a strong and reliable patent system? Read how new American patent law will change medical business plans.
Physician-consultants and medical device startups often don’t realize that failure to draft a tight physician-consultant contract could result in violations of federal laws and criminal and civil penalties. Read more about the guidelines for these contracts.
How will medtech and biotech companies be affected by the recently approved Leahy-Smith America Invents Act? Read more for five things these companies need to know about the modernized patent laws.
Healthcare entrepreneurs who have hit the intellectual property speed bump can relate to the appropriately named session, "Reducing Drag: New Approaches to IP Negotiation and Technology Licensing," at the Partnering for Cures conference earlier this week in New York City.
Investors in bioscience are looking not just for financial returns, but societal returns over the long haul in a global economy. And that will take collaborative efforts and a crowdsourcing of expertise as well as capital.
A frequent buzzword in business these days is "Big Data." But how do investors and developers in the biotechnology industry make the best use of it?
Is venture capital still viable as a model for funding new bioscience research, products and businesses?
Medical device startups could reap the benefits of patent reform, especially the shorter regulatory approval process that would allow companies to get their patents faster. Read more about the changes ahead for patent seekers.
At this week's Biotech 2011 conference, speakers from Teva Pharmaceutical Industries and Merck spoke about how biotech companies can survive in this tough regulatory and economic environment.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.